Sponsor: Gilead Sciences
Start Date: Started in 2013
Start Date: Projected to end in January 2022

Update:
Are in follow-up, the first participant reached their 360 week visit, the last participant is in the week 60 visit. The last participant will exit at least in their 96 week visit.
Project Details:

It is a Phase 2/3, Open-Label Study to confirm the dose of elvitegravir/cobicistat/emtricitabin e/tenofoviralafenamide (E/C/F/TAF) single tablet regimen (STR) in HIV-1 infected, antiretroviral (ARV) treatment naive adolescents and evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of E/C/F/TAF STR in HIV-1 infected, ART naive adolescents and virologically suppressed HIV- 1 infected children. Antiviral activity is determined by the achievement of HIV-1 RNA < 50 copies/mL at Weeks 24 and 48

Source of Funding / Funder: NIH/DAIDS
Sponsor: AIDS Clinical Trials Group
Start Date: Screening started April 2018. Enrollment closed October 2018
Start Date: Study stop date was July 2020

Summary:
Rifapentine-Containing Treatment Shortening Regimens for Pulmonary Tuberculosis

Update:
Closed
Project Details:

this is what i want to see

Source of Funding / Funder: NIH/DAIDS
Sponsor: AIDS Clinical Trials Group
Start Date: Screening started December 2017. Enrollment closed March 2019
Start Date: Projected stop date is March 2027

Summary:
Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE

Update:
181 participants enrolled. Three prematurely discontinued. 178 are currently in follow-up